| Literature DB >> 33732994 |
Ann C Miller1, Eva Tuiz2, Leah Shaw2, David Flood2, Pablo Garcia2, Eloin Dhaenens2, Dana R Thomson3, Joaquin Barnoya4, Carlos Mendoza Montano5, Peter Rohloff2,6.
Abstract
INTRODUCTION: Chronic kidney disease (CKD) is an emerging public health priority in Central America. However, data on the prevalence of CKD in Guatemala, Central America's most populous country, are limited, especially for rural communities.Entities:
Keywords: CKD; CKD of unknown etiology; Central America; global health
Year: 2021 PMID: 33732994 PMCID: PMC7938058 DOI: 10.1016/j.ekir.2020.12.015
Source DB: PubMed Journal: Kidney Int Rep ISSN: 2468-0249
Weighted prevalence estimates and error bounds of sociodemographic and occupational characteristics by site and by gender
| Characteristic | All | Estimates by site | Estimates by gender | ||
|---|---|---|---|---|---|
| Tecpán | San Antonio Suchitepéquez | Male | Female | ||
| Age, y | 39.5 (37.5–41.4) | 38.7 (36.4–41.0) | 41.3 (37.5–44.9) | 41.0 (39.0–42.9) | 39.3 (37.9–40.7) |
| Below national poverty line, % | 14.3 (10.5–18.1) | 9.9 (6.6–13.4) | 23.5 (15.4–31.5) | 20.6 (16.1–25.1) | 17.4 (14.3–20.5) |
| Education higher than primary school, % | 39.4 (33.3–45.8) | 39.7 (32.2–47.8) | 38.6 (28.9,49.2) | 43.1 (37.3–49.1) | 32.9 (28.9–37.3) |
| Self-identifies as indigenous, % | 80.4 (73.3–86.0) | 85.7 (76.2–91.8) | 69.2 (57.1–79.2) | 77.4 (70.9–82.9) | 75.3 (69.8–80.1) |
| In a couple/union, % | 70.1 (74.5–75.1) | 69.7 (62.1–76.4) | 70.5 (63.6–76.8) | 68.7 (63.1–73.8) | 68.7 (64.6–72.5) |
| Wage labor outside the home, % | 50.2 (45.3–55.1) | 50.3 (43.8–56.8) | 50.1 (43.8–56.3) | 84.7 (79.6–88.7) | 31.6 (27.5–36.0) |
| Any lifetime agriculture or construction, % | 52.5 (46.1–58.8) | 58.4 (49.8–66.5) | 39.1 (32.0–46.8) | 74.3 (68.2–79.6) | 35.2 (30.6–40.1) |
| If any lifetime agriculture, predominant crop | |||||
| Sugar cane, % | 10.1 (6.1–16.5) | 0.2 (0–1.4) | 44.1 (28.8–60.6) | 17.3 (11.6,24.9) | 8.8 (5.2–14.6) |
| Banana, % | 2.6 (0.8–7.8) | 1.1 (0.1–7.9) | 7.5 (2.0–24.2) | 2.5 (0.7–7.9) | 2.3 (0.9–6.1) |
| Coffee, % | 3.3 (1.9–7.5) | 3.2 (1.6–6.4) | 3.6 (1.6–7.6) | 3.1 (1.3–7.2) | 10.0 (6.2–15.8) |
| Vegetables, % | 27.1 (20.2–35.3) | 34.6 (25.2–45.3) | 1.6 (0.4–6.1) | 18.5 (12.9,25.7) | 35.3 (27.9–43.5) |
| Corn, % | 50.0 (40.0–60.0) | 54.1 (42.7–65.0) | 35.9 (20.4–55.0) | 52.4 (44.0,60.1) | 34.7 (27.5,42.7) |
| Other, % | 6.8 (4.0–11.4) | 6.7 (3.4–12.7) | 7.2 (3.4–14.5) | 6.1 (3.3–11.1) | 8.8 (5.2–14.6) |
| Typical daily hours worked in predominant crop labor | 7.4 (8.8–8.2) | 6.9 (6.3–7.4) | 9.3 (7.9–10.6) | 8.6 (8.0–9.3) | 6.7 (6.3–7.2) |
| Typical days/week worked in predominant crop labor | 4.6 (4.3–5.0) | 4.4 (4.0–4.7) | 5.6 (5.1–6.2) | 5.2 (4.9–5.5) | 4.6 (4.3–4.9) |
| Any lifetime agricultural pesticide exposure, % | 37.3 (31.5–43.6) | 37.9 (31.9–44.3) | 35.4 (20.7–53.6) | 52.3 (44.5–59.9) | 32.0 (25.3–39.6) |
| Grows own corn for consumption, % | 31.1 (22.6–41.1) | 44.2 (32.2–57.0) | 3.7 (1.4–9.5) | -- | -- |
All characteristics given as mean or percentage, with 95% confidence intervals in parentheses. Estimates of totals are provided for the site distribution using the overall sampling weights; separate gender-specific post-estimation weights are used for the gender estimates and comparisons.
P < 0.05.
Numbers pertain to n = 352 subjects who reported any lifetime agricultural work.
Weighted prevalence estimates and error bounds of clinical characteristics by site and by gender
| Characteristic | All | Estimates by site | Estimates by gender | ||
|---|---|---|---|---|---|
| Tecpán | San Antonio Suchitepéquez | Male | Female | ||
| Systolic BP, mm Hg | 110 (108–112) | 108 (106–110) | 117 (114–120) | 118 (115–120) | 109 (107–110) |
| Diastolic BP, mm Hg | 74 (73–75) | 73 (71–75) | 76 (74–77) | 76 (74–77) | 73 (72–74) |
| Hypertension, % | 8.6 (6.3–11.7) | 7.0 (4.6–10.4) | 12.4 (7.6–19.5) | 12.8 (9.4–17.2) | 8.2 (6.1–10.9 |
| Hypertension, or self-report history of hypertension, % | 20.7 (17.4–24,4) | 21.8 (17.8–26.4) | 18.2 (12.9–25.0) | 20.1 (15.9–25.1) | 21.0 (17.7–24.7) |
| Glycosylated hemoglobin ≥6.5%, % | 9.3 (7.1–12.2) | 8.2 (5.5–11.9) | 11.9 (8.1–17.0) | 10.7 (7.5–15.0) | 13.6 (10.9–16.8) |
| Glycosylated hemoglobin, if ≥6.5% | 10.0 (9.3–10.7) | 10.2 (9.2–11.3) | 9.6 (8.9,10.4) | 10.1 (9.1–11.1) | 9.6 (9.0–10.1) |
| Glycosylated hemoglobin ≥6.5% or self-report of diabetes, % | 12.3 (9.4–15.8) | 11.4 (7.9–16.2) | 14.2 (10.2–19.5) | 14.0 (10.4–18.6) | 15.7 (12.9–19.0) |
| Height, cm | 150.7 (149.8–151.6) | 149.8 (148.7–150.9) | 152.7 (151.3–154.1) | 158.6 (157.7–159.5) | 146.5 (145.9–147.1) |
| Body mass index (BMI) | 27.1 (26.6–27.6) | 27.2 (26.6–27.7) | 27.0 (25.9–28.1) | 25.7 (25.1–26.3) | 28.0 (27.4–28.5) |
| Obese (BMI ≥ 30), % | 25.1 (21.0–29.7) | 23.7 (18.9–29.2) | 28.3 (21.2–36.6) | 14.0 (10.2–19.0) | 33.5 (29.4–37.7) |
| Overweight (BMI ≥ 25, < 30), % | 39.3 (32.8–46.1) | 41.2 (32.5–50.4) | 34.9 (28.8–41.5) | 43.2 (37.0–49.5) | 33.3 (29.2–37.6) |
| EGFR | |||||
| <60 ml/min per 1.73 m2, % | 4.0 (2.4–6.6) | 2.7 (1.1–6.2) | 7.0 (3.7–12.8) | 3.3 (1.7–6.2) | 3.3 (2.1–5.1) |
| ≥ 60, <90, % | 20.6 (17.0–24.7) | 22.7 (18.0–28.1) | 16.3 (11.8–22.2) | 25.8 (21.0–31.3) | 16.3 (13.1–20.0) |
| Any lifetime ethanol consumption, % | 56.0 (50.5–61.6) | 56.6 (49.1–63.8) | 54..7 (48.8–60.5) | 71.7 (65.8–77.0) | 45.8 (41.0–50.7) |
| Any lifetime tobacco use, % | 25.4 (21.9–29.2) | 25.3 (21.1–30.0) | 25.5 (19.6–32.4) | 58.4 (52.3–64.2) | 8.1 (6.1–10.7) |
| Any prolonged NSAID use, % | 93.0 (89.7–95.3) | 91.0 (86.4–94.1) | 97.6 (92.8–99.2) | 94.5 (91.1–96.6) | 93.2 (90.5–95.1) |
| Family history of diabetes or hypertension, % | 54.9 (49.0–60.7) | 57.6 (50.4–64.5) | 48.8 (39.0–58.6) | 57.5 (50.8–63.8) | 54.8 (49.8–59.6) |
| Self-reported history of diabetes or hypertension, % | 21.4 (18.0–25.2) | 23.9 (19.4–29.1) | 15.7 (11.8–20.7) | 19.5 (15.3–24.6) | 21.8 (18.4–25.4) |
| Self-reported history of child malnutrition or prematurity, % | 6.3 (4.2–9.3) | 7.7 (4.7–12.1) | 3.7 (2.1–6.5) | 5.4 (3.2–9.1) | 6.4 (4.5–9.0) |
NSAID, nonsteroidal anti-inflammatory drug.
All characteristics given as mean or percentage, with 95% confidence intervals in parentheses. Total estimates are provided for the site distribution using the overall sampling weights; separate gender-specific post-estimation weights are used for the gender estimates and comparisons.
P < 0.05.
Defined as systolic blood pressure (BP) ≥ 140 mm Hg or diastolic BP ≥ 90 mm Hg.
P < 0.10.
All individuals with measured systolic BP ≥ 140 mm Hg or diastolic BP ≥ 90 mm Hg or self-reported history of hypertension.
All individuals with measured glycosylated hemoglobin ≥6.5% or self-reported history of diabetes.
GFR estimated using the Chronic Kidney Disease–Epidemiology Collaboration equation.
Defined as self-reported daily use for ≥ 3 months.
Figure 1Flow chart of sample recruitment and enrollment.
Figure 2Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Risk Classification for study population. All numbers are survey-weighted counts and frequencies. GFR, glomerular filtration rate.
Logistic regression analysis for factors associated with any abnormal eGFR <60 ml/min per 1.73 m2
| Characteristic | Unadjusted OR | Adjusted OR |
|---|---|---|
| Lives in hot climate (San Antonio Suchitepéquez) | 2.78 [0.94–8.25] | -- |
| Age, y | 1.10 [1.06–1.14] | 1.12 [1.06–1.19] |
| Below national poverty line | 1.01 [0.99–1.03] | 0.93 [0.87–0.99] |
| Agricultural experience | ||
Sugar cane | 10.25 [2.89–36.29] | 0.57 [0.06–5.17] |
Banana | 4.55 [0.45–46.45] | -- |
Coffee | 6.03 [1.29–28.18] | -- |
Vegetables | 1.28 [0.27–5.97] | -- |
Corn | 0.60 [0.17–2.20] | -- |
| Interaction between poverty and history of employment in sugar cane | 1.10 [1.01–1.19] | |
| History of diabetes or hypertension | 7.20 [1.89–27.35] | 11.21 [3.28–38.24] |
| Weight status | ||
Underweight (BMI < 18.5) | 5.82 [0.80–42.08] | 21.09 [2.05–217.0] |
Overweight/Obese (BMI ≥ 25) | 0.52 [0.16–1.65] | 0.72 [0.25–2.06] |
| Any lifetime tobacco use | 3.05 [0.92–10.12] | -- |
BMI, body mass index; eGFR, estimated glomerular filtration rate; OR, odds ratio
P < 0.05.
All individuals with measured systolic blood pressure (BP) ≥140 mm Hg or diastolic BP ≥90 mm Hg, measured glycosylated hemoglobin ≥ 6.5%, or self-reported history of hypertension or diabetes
P < 0.10.
Figure 3Glomerular filtration rate (GFR) classification on confirmatory testing. Confirmatory testing was available for 63 subjects. Cells are color-coded as green (no change in GFR classification), blue (improved GFR classification), and yellow (worsened GFR classification).